Editas Medicine, Inc.
EDIT Healthcare Biotechnology
Editas Medicine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.5 million, up 25.4% from fiscal 2024. In the quarter to June 2026, revenue grew 232.3%, EPS grew 76.2% and free cash flow grew 40.7%, each against the same quarter a year earlier.
Follow EDIT
Editas Medicine, Inc. (EDIT) Beneish M-score
Editas Medicine, Inc.'s Beneish M-score for fiscal 2025 is −2.46; values above −1.78 are the model's flag for possible earnings manipulation — a statistical screen, not a finding.
Beneish M-score, annual
Embed this chart
Annual newest first
| Period | Beneish M-score | Change (points) |
|---|---|---|
| FY2025 | −2.46 | (9.51) |
| FY2024 | 7.05 | 7.21 |
| FY2023 | −0.16 | (18.97) |
| FY2022 | 18.81 | 23.38 |
| FY2021 | −4.56 | (8.98) |
| FY2020 | 4.42 | (12.54) |
| FY2019 | 16.96 | 18.96 |
| FY2018 | −2.01 | (1.47) |
| FY2017 | −0.54 | 2.62 |
| FY2016 | −3.16 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Days’ sales in receivables index | 0.74 | — | 0.68 | |
| Gross margin index | 1.00 | — | 0.53 | |
| Asset quality index | 0.93 | — | 0.37 | |
| Sales growth index | 1.25 | — | 1.12 | |
| Depreciation index | 0.00 | — | 0.00 | |
| SG&A index | 0.55 | — | −0.10 | |
| Total accruals to total assets | 0.03 | — | 0.13 | |
| Leverage index | 1.10 | — | −0.36 | |
| Beneish M-score | Low — no pattern the model associates with manipulation | −2.46 | ||
How the Beneish M-score works
M = −4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI (Beneish, 1999): eight changes in the accounts from one fiscal year to the next, which the model weighs for the pattern seen in companies that later restated their earnings. Higher is worse.
| below −2.22 | Low — no pattern the model associates with manipulation |
|---|---|
| −2.22 to −1.78 | Elevated |
| above −1.78 | Flagged by the model |
−1.78 is the cut-off usually quoted from the paper, −2.22 a common conservative one. A statistical screen, not a finding of wrongdoing.
When asset quality, depreciation or SG&A cannot be worked out, that index is set to 1, as Beneish did, and the breakdown says so; with all three missing there is no score. Depreciation includes amortisation, and asset quality leaves out securities. Not worked out for banks, insurers and REITs.
Beneish M-score against peers
| Company | Beneish M-score |
|---|---|
| CAPR Capricor Therapeutics, Inc. compare | −2.6× |
| EDIT Editas Medicine, Inc. | −2.5× |
| SPRY ARS Pharmaceuticals, Inc. compare | −0.4× |
| PRTCY PureTech Health PLC Sponsored ADR compare | 1.5× |
| ENTX Entera Bio Ltd. compare | — |
| DMAC DiaMedica Therapeutics, Inc. compare | — |
| TECX Tectonic Therapeutic, Inc. compare | — |
| RZLT Rezolute, Inc. compare | — |
| PRTA Prothena Corporation plc compare | — |
What Beneish M-score is
The Beneish M-Score combines eight year-on-year changes in the accounts into a statistical screen for patterns seen in companies that overstated earnings.
−4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI